Trial of Prasinezumab in Early-Stage Parkinson’s Disease

Trial of Prasinezumab in Early-Stage Parkinson’s Disease
N Engl J Med. 2022 Aug 4;387(5):421-432. doi: 10.1056/NEJMoa2202867.ABSTRACTBACKGROUND: Aggregated α-synuclein plays an important role in the pathogenesis of Parkinson's disease. The monoclonal antibody prasinezumab, directed at aggregated α-synuclein, is being studied for its effect on Parkinson's disease.METHODS: In this phase 2 trial, we randomly assigned participants with early-stage Parkinson's disease in a 1:1:1 ratio to receive intravenous placebo or ... read more
Source: PubMedPublished on 2022-08-03By Gennaro Pagano